Growth hormone is a cellular senescence target in pituitary and nonpituitary cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 35, 2013, Pages

  Chesnokova, Vera ^a   Zhou, Cuiqi ^a   Ben Shlomo, Anat ^a   Zonis, Svetlana ^a   Tani, Yuji ^a   Ren, Song Guang ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acromegaly; Pituitary hormone

Indexed keywords

GROWTH HORMONE; PROTEIN P21; PROTEIN P53; CAYLIN2; ETOPOSIDE; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL AGING; CONTROLLED STUDY; DNA DAMAGE; GENETIC TRANSCRIPTION; HORMONE BINDING; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS; HYPOPHYSIS CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; UPREGULATION; ADENOMA; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOMA; ANIMALS; CELL AGING; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; ETOPOSIDE; GROWTH HORMONE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C57BL; PIPERAZINES; PITUITARY GLAND; PITUITARY NEOPLASMS; PROMOTER REGIONS, GENETIC; RATS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883334461     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310589110     Document Type: Article

References (77)

1. Campisi J (2005) Suppressing cancer: The importance of being senescent. Science 309(5736):886-887.
2. Sharpless NE, DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113(2):160-168.
3. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24(22):2463-2479.
4. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593-602.
5. Coppé JP, et al. (2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 5(2): e9188.
6. Levy A, Lightman S (2003) Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 24(2):94-127.
7. Farrell WE (2006) Pituitary tumours: Findings from whole genome analyses. Endocr Relat Cancer 13(3):707-716.
8. Farrell WE, Clayton RN (2003) Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10(2):323-330.
9. Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112(11):1603-1618.
10. Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5):257-266.
11. Wierinckx A, et al. (2010) Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326(1-2):30-39.
12. Kovacs K, Horvath E, Vidal S (2001) Classification of pituitary adenomas. J Neurooncol 54(2):121-127.
13. Chesnokova V, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67(21):10564-10572.
14. Chesnokova V, et al. (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105(45):17498-17503.
15. Abbud RA, et al. (2005) Early multipotential pituitary focal hyperplasia in the alphasubunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 19(5):1383-1391.
16. Yu R, Lu W, Chen J, McCabe CJ, Melmed S (2003) Overexpressed pituitary tumortransforming gene causes aneuploidy in live human cells. Endocrinology 144(11): 4991-4998.
17. Donangelo I, et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147(10):4781-4791.
18. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4):765-770, discussion 770-771.
19. Wierinckx A, et al. (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14(3):887-900.
20. Scheithauer BW, et al. (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341-353, discussion 341-353.
21. Suliman M, et al. (2001) Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54(3):317-325.
22. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137(3):413-431.
23. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724-737.
24. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844-848.
25. Waters MJ, Conway-Campbell BL (2004) The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci USA 101(42):14992-14993.
26. Brunet-Dunand SE, et al. (2009) Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150(3):1341-1352.
27. Perry JK, Emerald BS, Mertani HC, Lobie PE (2006) The oncogenic potential of growth hormone. Growth Horm IGF Res 16(5-6):277-289.
28. Carter-Su C, Schwartz J, Smit LS (1996) Molecular mechanism of growth hormone action. Annu Rev Physiol 58:187-207.
29. Clemmons DR (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113(1):25-27.
30. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535-559.
31. Zhao JT, et al. (2011) Identification of novel GH-regulated pathway of lipid metabolism in adipose tissue: A gene expression study in hypopituitary men. J Clin Endocrinol Metab 96(7):E1188-E1196.
32. Liu Y, Bodmer WF (2006) Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 103(4):976-981.
33. Vojtěsek B, Lane DP (1993) Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105(Pt 3):607-612.
34. Kyle CV, Evans MC, Odell WD (1981) Growth hormone-like material in normal human tissues. J Clin Endocrinol Metab 53(6):1138-1144.
35. Khoury MP, Bourdon JC (2011) p53 isoforms: An intracellular microprocessor? Genes Cancer 2(4):453-465.
36. Pan D, et al. (2013) Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS ONE 8(1):e54006.
37. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282(5393):1497-1501.
38. Kurz DJ, Decary S, Hong Y, Erusalimsky JD (2000) Senescence-associated (beta)- galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113(Pt 20):3613-3622.
39. Arnold RE, Weigent DA (2004) The inhibition of apoptosis in EL4 lymphoma cells overexpressing growth hormone. Neuroimmunomodulation 11(3):149-159.
40. Svensson AL, Bucht N, Hallberg M, Nyberg F (2008) Reversal of opiate-induced apoptosis by human recombinant growth hormone in murine foetus primary hippocampal neuronal cell cultures. Proc Natl Acad Sci USA 105(20):7304-7308.
41. Brent GA, Larsen PR, Harney JW, Koenig RJ, Moore DD (1989) Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co-transfected beta type thyroid hormone receptor. J Biol Chem 264(1):178-182.
42. Schaufele F (1996) CCAAT/enhancer-binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GHFT1-5 cells. J Biol Chem 271(35): 21484-21489.
43. Fox SR, et al. (1990) The homeodomain protein, Pit-1/GHF-1, is capable of binding to and activating cell-specific elements of both the growth hormone and prolactin gene promoters. Mol Endocrinol 4(7):1069-1080.
44. Copp RP, Samuels HH (1989) Identification of an adenosine 3′,5′-monophosphate (cAMP)-responsive region in the rat growth hormone gene: evidence for independent and synergistic effects of cAMP and thyroid hormone on gene expression. Mol Endocrinol 3(5):790-796.
45. Ho Y, Liebhaber SA, Cooke NE (2011) The role of the hGH locus control region in somatotrope restriction of hGH-N gene expression. Mol Endocrinol 25(5):877-884.
46. Chesnokova V, et al. (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS ONE 6(3):e17924.
47. Bando H, et al. (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39(4):355-363.
48. Yamada S, et al. (1993) Growth hormone-producing pituitary adenomas: Correlations between clinical characteristics and morphology. Neurosurgery 33(1):20-27.
49. Mazal PR, et al. (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of acromegalic patients. Clin Neuropathol 20(4):163-171.
50. Obari A, et al. (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82-91.
51. Kiseljak-Vassiliades K, et al. (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1):18-28.
52. Kleinberg DL, Ruan W (2008) IGF-I, GH, and sex steroid effects in normal mammary gland development. J Mammary Gland Biol Neoplasia 13(4):353-360.
53. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL (1999) Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140(5):1984-1989.
54. Nyberg F (2000) Growth hormone in the brain: Characteristics of specific brain targets for the hormone and their functional significance. Front Neuroendocrinol 21(4): 330-348.
55. Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19(6): 717-797.
56. Brooks AJ, Waters MJ (2010) The growth hormone receptor: Mechanism of activation and clinical implications. Nat Rev Endocrinol 6(9):515-525.
57. Ceseña TI, et al. (2007) Multiple mechanisms of growth hormone-regulated gene transcription. Mol Genet Metab 90(2):126-133.
58. DiGirolamo DJ, et al. (2007) Mode of growth hormone action in osteoblasts. J Biol Chem 282(43):31666-31674.
59. Cannata D, Vijayakumar A, Fierz Y, LeRoith D (2010) The GH/IGF-1 axis in growth and development: New insights derived from animal models. Adv Pediatr 57(1):331-351.
60. List EO, et al. (2011) Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr Rev 32(3):356-386.
61. Barclay JL, et al. (2010) In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. Mol Endocrinol 24(1):204-217.
62. Brooks AJ, Wooh JW, Tunny KA, Waters MJ (2008) Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol 40(10):1984-1989.
63. Lobie PE, et al. (1996) Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology 137(9):4037-4045.
64. Xu XQ, et al. (2005) Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J Biol Chem 280(25):23987-24003.
65. Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355(24):2558-2573.
66. Zhu T, et al. (2005) Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65(1):317-324.
67. Mukhina S, et al. (2004) Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101(42):15166-15171.
68. Ruan W, Kleinberg DL (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140(11):5075-5081.
69. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 98(21):12072-12077.
70. Bavik C, et al. (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66(2):794-802.
71. Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83(3-4):179-188.
72. Kulig E, et al. (1999) Apoptosis in nontumorous and neoplastic human pituitaries: Expression of the Bcl-2 family of proteins. Am J Pathol 154(3):767-774.
73. Nakonechnaya AO, Jefferson HS, Chen X, Shewchuk BM (2013) Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival. J Cell Biochem 114(6):1322-1335.
74. Bustamante JJ, et al. (2010) Human growth hormone: 45-kDa isoform with extraordinarily stable interchain disulfide links has attenuated receptor-binding and cell-proliferative activities. Growth Horm IGF Res 20(4):298-304.
75. Delbridge AR, Valente LJ, Strasser A (2012) The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol, 10.1101/cshperspect.a008789.
76. Coppé JP, et al. (2008) Senescence-associated secretory phenotypes reveal cellnonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853-2868.
77. Endo S, et al. (2011) Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 102(3):605-613.